IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1126-1150 out of 1216.

<< < 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 > >>

Public Release: 14-Feb-2013
Cell Host & Microbe
Discovery in HIV may solve efficiency problems for gene therapy
Case Western Reserve researchers pinpoint RNA element missing from viral vectors.

Contact: Jessica Studeny
jessica.studeny@case.edu
216-368-4692
Case Western Reserve University

Public Release: 14-Feb-2013
American Journal of Public Health
Study shows alcohol consumption is a leading preventable cause of cancer death in the US
Researchers from the Boston University School of Medicine and Boston University School of Public Health have shown that alcohol is a major contributor to cancer deaths and years of potential life lost. These findings, published in the Apr. 2013 issue of the American Journal of Public Health, also show that reducing alcohol consumption is an important cancer prevention strategy as alcohol is a known carcinogen even when consumed in small quantities.

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center

Public Release: 14-Feb-2013
Journal of the National Cancer Institute
The role of radical prostatectomy in patients with prostate cancer
Even in the presence of screening, there is benefit to radical prostatectomy (RP) in prostate cancer patients, however, the benefit is limited to a subgroup of patients and can take years to become evident according to a study published Feb. 14 in the Journal of the National Cancer Institute.

Contact: Zachary Rathner
rathnerzm@gmail.com
919-677-2697
Journal of the National Cancer Institute

Public Release: 14-Feb-2013
Lancet Oncology
Researchers discover breakthrough in ovarian cancer
Researchers at The University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix have discovered that many women with low-grade serous carcinoma of the ovary or peritoneum have seen their tumors stabilize or shrink after taking a regular dose of the compound selumetinib.

Contact: Lynne Reaves
602-406-4734
St. Joseph's Hospital and Medical Center

Public Release: 14-Feb-2013
PLOS ONE
Combo of Avastin, second drug shows promise fighting brain cancer, Mayo Clinic finds
The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain for reasons no one previously has understood. Now, Mayo Clinic researchers have found out why this happens.
National Institutes of Health

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic

Public Release: 14-Feb-2013
Cell
Study tracks leukemia's genetic evolution, may help predict disease course, tailor care
A study led by Dana-Farber Cancer Institute and the Broad Institute researchers shows how gene mutations shift and evolve over time in chronic lymphocytic leukemia (CLL). This evolution, they report, holds the key to understanding why CLL often recurs after treatment and helps explain why patients with a seemingly similar disease often don't derive the same benefit from therapy and why therapy itself may speed the recurrence of the disease.
National Institutes of Health, Melton and Rosenbach Funds, ASH, Blavatnik Family Foundation, ACS, Damon Runyon Cancer Research Foundation, American Association for Cancer Research

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute

Public Release: 14-Feb-2013
Clinical Cancer Research
Hopkins scientists create method to personalize chemotherapy drug selection
In laboratory studies, scientists at the Johns Hopkins Kimmel Cancer Center have developed a way to personalize chemotherapy drug selection for cancer patients by using cell lines created from their own tumors.
National Institutes of Health, Sol Goldman Pancreatic Cancer Research

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 14-Feb-2013
Blood
Risk of leukemia after cancer chemotherapy persists
While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients remain at risk of developing treatment-related leukemia, according to results of a study published online today in Blood, the Journal of the American Society of Hematology.

Contact: Andrea Slesinski
aslesinski@hematology.org
American Society of Hematology

Public Release: 14-Feb-2013
Aging Cell
Low-protein diet slows Alzheimer's in mice
Mice with many of the pathologies of Alzheimer's disease showed fewer signs of the disease when given a protein-restricted diet supplemented with specific amino acids every other week for four months.
National Institutes of Health

Contact: Robert Perkins
perkinsr@usc.edu
213-740-9226
University of Southern California

Public Release: 14-Feb-2013
Journal of Biological Chemistry
Indian plant could play key role in death of cancer cells
Scientists at the Georgia Regents University Cancer Center have identified an Indian plant, used for centuries to treat inflammation, fever and malaria, that could help kill cancer cells.

Contact: Danielle Moores
dwongmoores@yahoo.com
706-496-5956
Medical College of Georgia at Georgia Regents University

Public Release: 13-Feb-2013
PLOS ONE
California's Tobacco Control Program generates huge health care savings, UCSF study shows
Over a span of nearly 20 years, California's tobacco control program cost $2.4 billion and reduced health care costs by $134 billion, according to a new study by UC San Francisco.
NIH/National Cancer Institute, TRDRP

Contact: Elizabeth Fernandez
elizabeth.fernandez@ucsf.edu
415-502-6397
University of California - San Francisco

Public Release: 13-Feb-2013
Cell Host & Microbe
UNC researchers discover gene that suppresses herpesviruses
Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus hide within the worldwide human population. While dormant in the vast majority of those infected, these active herpesviruses can develop into several forms of cancer. In an effort to understand and eventually develop treatments for these viruses, researchers at the University of North Carolina have identified a family of human genes known as Tousled-like kinases that play a key role in the suppression and activation of these viruses.
National Institutes of Health, UNC Lineberger

Contact: William Davis
william_davis@med.unc.edu
919-962-3405
University of North Carolina Health Care

Public Release: 13-Feb-2013
Annals of Oncology
Copper depletion therapy keeps high-risk triple-negative breast cancer at bay
An anti-copper drug compound that disables the ability of bone marrow cells from setting up a "home" in organs to receive and nurture migrating cancer tumor cells has shown surprising benefit in one of the most difficult-to-treat forms of cancer -- high-risk triple-negative breast cancer.
Anne Moore Breast Cancer Research Fund, Stephen and Madeline Anbinder Foundation

Contact: Lauren Woods
Law2014@med.cornell.edu
646-317-7401
Weill Cornell Medical College

Public Release: 13-Feb-2013
Oncologist
Researchers discover biological diversity in triple-negative breast cancer
A team lead by Charles Perou, Ph.D., UNC Lineberger Comprehensive Cancer Center, examined more than 1,700 breast tumors, including 412 triple negative breast cancers, and concluded that triple-negative cancers and basal-like breast cancers should not be considered a single type.
National Institutes of Health, NIH/ National Cancer Institute, Breast Cancer Research Foundation, Sociedad Espanola de Oncología Medica

Contact: William Davis
william_davis@med.unc.edu
919-962-3405
University of North Carolina Health Care

Public Release: 13-Feb-2013
Cancer Research
Protein central to cancer stem cell formation provides new potential target
Researchers have identified a pivotal protein in a cellular transformation that makes a cancer cell more resistant to treatment and more capable of growing and spreading, making it an inviting new target for drug development.

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center

Public Release: 13-Feb-2013
Journal of Pediatric Oncology Nursing
Tube versus IV feeding in malnourished pediatric cancer patients
About 60 percent of pediatric cancer patients experience malnourishment during treatment. At that point, patients and families have a choice: tube feeding or IV nutrition supplement. Which would you choose? A study published this week in the Journal of Pediatric Oncology Nursing shows that families' perceptions, especially of the discomfort of tube feeding, leads to choosing IV over tube – despite the fact that tube feeding is usually the better choice, associated with better gut function and lower rates of infection.
Rebecca Slye Endowment Grant

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 13-Feb-2013
New England Journal of Medicine
Drug shown to reverse radioiodine resistance in some advanced thyroid cancers
Memorial Sloan-Kettering Cancer Center researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients' thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.

Contact: Caitlin Hool
HOOLC@MSKCC.ORG
212-639-3573
Memorial Sloan-Kettering Cancer Center

Public Release: 13-Feb-2013
Journal of Clinical Oncology
Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer
Cleveland Clinic develops clinical screening program for the number one genetic cause of colon cancer. Eight-year study addresses Lynch syndrome.

Contact: Laura Ambro
ambrol@ccf.org
216-636-5876
Cleveland Clinic

Public Release: 13-Feb-2013
Journal of Clinical Investigation
Key molecule suppresses growth of cancerous liver tumors, Mayo study finds
A molecule already implicated in a number of diverse cellular functions can suppress the growth of tumors in the liver, a Mayo Clinic Cancer Center study has found. Its name is IQGAP1, and when the molecule is active in the cells that surround a tumor cell, this "tumor microenvironment" becomes less hospitable to cancer growth. When the molecule is deficient, cancer thrives.
National Institutes of Health

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 12-Feb-2013
Journal of Clinical Oncology
Study shows that problem-solving training helps mothers cope with child's cancer diagnosis
A multi-site clinical trial of BRIGHT Ideas problem-solving training shows durable benefits in mothers of children diagnosed with cancer. Study published in Journal of Clinical Oncology. Materials available for download and use!
NIH/National Cancer Institute

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 12-Feb-2013
2013 Genitourinary Cancers Symposium
Research from the 2013 Genitourinary Cancers Symposium highlights new insights on high-risk prostate cancer prevalence and treatment, compares benefit of surveillance and surgery for management of small kidney tumors
Research on promising new therapies and data on the relative benefits of established treatments for genitourinary cancers were released today, in advance of the fourth annual Genitourinary Cancers Symposium, being held Feb. 14-16, 2013, at the Rosen Shingle Creek in Orlando, FL.

Contact: Kelly Baldwin
kelly.baldwin@asco.org
571-483-1365
American Society of Clinical Oncology

Public Release: 12-Feb-2013
Genes and Development
Molecular master switch for pancreatic cancer identified, potential predictor of treatment outcome
A recently described master regulator protein may explain the development of aberrant cell growth in the pancreas spurred by inflammation. The Penn team profiled gene expression of mouse pancreatic ductal and duct-like cells from different states -- embryonic development, acute pancreatitis and K-ras mutation-driven carcinogenesis -- to find the molecular regulation of these processes.
NIH/National Institute of Diabetes and Digestive and Kidney Diseases, National Pancreas Foundation

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.ed
215-349-5658
University of Pennsylvania School of Medicine

Public Release: 12-Feb-2013
Cancer Discovery
Emerging cancer drugs may drive bone tumors
Cancer drugs should kill tumors, not encourage their spread. But new evidence suggests that an otherwise promising class of drugs may actually increase the risk of tumors spreading to bone, according to researchers at Washington University School of Medicine in St. Louis.
National Institutes of Health, and others

Contact: Julia Evangelou Strait
straitj@wustl.edu
314-286-0141
Washington University School of Medicine

Public Release: 12-Feb-2013
Experimental and Clinical Psychopharmacology
UTHealth: Alcohol consumption may be in response to smoking cessation
New findings by researchers at the University of Texas Health Science Center at Houston School of Public Health may help identify situations in which smokers who are trying to quit are at a higher risk of relapse.
NIH/National Cancer Institute, American Cancer Society

Contact: Stephanie Logue
stephanie.d.logue@uth.tmc.edu
713-500-3307
University of Texas Health Science Center at Houston

Public Release: 12-Feb-2013
Journal of American Chemical Society
Detecting cocaine 'naturally'
Since the beginning of time, living organisms have developed ingenious mechanisms to monitor their environment. As part of an international study, a team of researchers has adapted some of these natural mechanisms to detect specific molecules such as cocaine more accurately and quickly. Their work may greatly facilitate the rapid screening -- less than five minutes -- of many drugs, infectious diseases, and cancers.
Italian Ministry of University and Research, Bill & Melinda Gates Foundation, and others

Contact: Julie Gazaille
j.cordeau-gazaille@umontreal.ca
514-343-6796
University of Montreal

Showing releases 1126-1150 out of 1216.

<< < 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 > >>

  Search News Releases

     

 

 

EurekAlert!